Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing (Q39586890)

13 September 2017

title

Antimicrobial susceptibility and synergy studies of cystic fibrosis sputum by direct sputum sensitivity testing (English)

1 reference

13 September 2017

0 references

0 references

D J Serisier

1

1 reference

13 September 2017

A Tuck

2

1 reference

13 September 2017

D Matley

3

1 reference

13 September 2017

M P Carroll

4

1 reference

13 September 2017

G Jones

5

1 reference

13 September 2017

publication date

12 July 2012

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

13 September 2017

published in

1 reference

13 September 2017

volume

31

1 reference

13 September 2017

issue

11

1 reference

13 September 2017

page(s)

3211-3216

1 reference

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1687-6

Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22790537

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10096-012-1687-6

1 reference

13 September 2017

1 reference